MIST logo

MIST
Milestone Pharmaceuticals Inc

7,211
Mkt Cap
$247.1M
Volume
1.69M
52W High
$3.06
52W Low
$0.9777
PE Ratio
-2.56
MIST Fundamentals
Price
$2.04
Prev Close
$2.10
Open
$2.09
50D MA
$1.66
Beta
1.51
Avg. Volume
2.04M
EPS (Annual)
-$0.7517
P/B
5.19
Rev/Employee
$40,684.21
$121.86
Loading...
Loading...
News
all
press releases
Joseph Oliveto Sells 36,500 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock
Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) CEO Joseph Oliveto sold 36,500 shares of the firm's stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $2.26, for a total value of $82,490.00. Following the completion of the sale, the chief...
MarketBeat·9h ago
News Placeholder
More News
News Placeholder
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded to Strong-Buy at Raymond James Financial
Raymond James Financial raised Milestone Pharmaceuticals to a "strong-buy" rating in a research note on Thursday...
MarketBeat·10d ago
News Placeholder
Milestone Pharmaceuticals (NASDAQ:MIST) Lowered to "Sell" Rating by Wall Street Zen
Wall Street Zen downgraded shares of Milestone Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·10d ago
News Placeholder
Raymond James Financial Initiates Coverage on Milestone Pharmaceuticals (NASDAQ:MIST)
Raymond James Financial began coverage on Milestone Pharmaceuticals in a report on Friday. They issued a "strong-buy" rating and a $6.00 price objective on the stock...
MarketBeat·11d ago
News Placeholder
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from Brokerages
Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) has been assigned an average recommendation of "Hold" from the six ratings firms that are currently covering the company, Marketbeat.com...
MarketBeat·22d ago
News Placeholder
Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen upgraded Milestone Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·24d ago
News Placeholder
Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Tuesday
Milestone Pharmaceuticals (NASDAQ:MIST) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 31. (View Earnings Report at...
MarketBeat·28d ago
News Placeholder
Equities Analysts Issue Forecasts for MIST FY2028 Earnings
Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Equities researchers at HC Wainwright lowered their FY2028 earnings per share estimates for shares of Milestone Pharmaceuticals in a research report issued on Friday, March 20th. HC Wainwright analyst B. Folkes now forecasts that the compa...
MarketBeat·29d ago
News Placeholder
Milestone Pharmaceuticals (NASDAQ:MIST) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. The firm had revenue of $1.44 million during the quarter, compared to the...
MarketBeat·1mo ago
News Placeholder
Milestone Pharmaceuticals Q4 Earnings Call Highlights
Milestone Pharmaceuticals (NASDAQ:MIST) executives highlighted the company's transition to commercialization during a year-end 2025 update call, following the U.S. Food and Drug Administration's...
MarketBeat·1mo ago
<
1
2
...
>

Latest MIST News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.